COMPANY

Promentis Pharmaceuticals

HQ: Milwaukee, WI source · promentispharma.com ↗ · Midwest

Keywords: neurology psychiatry schizophrenia Trichotillomania Impulse Control Disorders autism spectrum disorder fragile x syndrome phelan-mcdermid syndrome SXC-2023

Location: Milwaukee, WI · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)6NIH grants

Timeline

Mar 4, 2019 Trial start Phase 2: Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal source ↗
Dec 19, 2018 Trial start Phase 2: A Study in Patients With Trichotillomania source ↗
Apr 26, 2018 Trial start Phase 1: Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023 source ↗
Sep 11, 2017 Trial start Phase 1: Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT03797521	A Study in Patients With Trichotillomania	Phase 2	Completed	Dec 19, 2018	Dec 2, 2019 (actual)
NCT03887429	Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal	Phase 2	Completed	Mar 4, 2019	Jul 2, 2019 (actual)
NCT03301298	Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers	Phase 1	Completed	Sep 11, 2017	Feb 13, 2018 (actual)
NCT03542435	Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023	Phase 1	Completed	Apr 26, 2018	Aug 8, 2018 (actual)

NIH awards 6

Annual award amounts. Total $2.5M.

Sep 23, 2015 NIH award 1R43HD084038-01A1 FY2015: $151,366 awarded for that fiscal year; activity R43 (SBIR); PI BEYER, CHAD EDWARD; recipient as written: PROMENTIS PHARMACEUTICALS, INC., MILWAUKEE, WI. Targeting System Xc- for th source ↗
Jun 26, 2014 NIH award 5R44MH083417-05 FY2014: $600,000 awarded for that fiscal year; activity R44 (SBIR); PI BEYER, CHAD EDWARD; recipient as written: PROMENTIS PHARMACEUTICALS, INC., MILWAUKEE, WI. Targeting System Xc- for the source ↗
Jul 6, 2013 NIH award 5R44MH083417-04 FY2013: $600,000 awarded for that fiscal year; activity R44 (SBIR); PI BEYER, CHAD EDWARD; recipient as written: PROMENTIS PHARMACEUTICALS, INC., MILWAUKEE, WI. Targeting System Xc- for the source ↗
Sep 14, 2012 NIH award 2R44MH083417-03 FY2012: $600,000 awarded for that fiscal year; activity R44 (SBIR); PI BEYER, CHAD EDWARD; recipient as written: PROMENTIS PHARMACEUTICALS, INC., MILWAUKEE, WI. Targeting System Xc- for the source ↗
Jul 1, 2009 NIH award 5R43MH083417-02 FY2009: $250,489 awarded for that fiscal year; activity R43 (SBIR); PI POLLOCK, STEVEN R; recipient as written: PROMENTIS PHARMACEUTICALS, INC., MILWAUKEE, WI. Development of Compounds Targe source ↗
Sep 24, 2008 NIH award 1R43MH083417-01 FY2008: $257,880 awarded for that fiscal year; activity R43 (SBIR); PI POLLOCK, STEVEN R; recipient as written: PROMENTIS PHARMACEUTICALS, INC., MILWAUKEE, WI. Development of Compounds Targe source ↗